

**The YODA Project**  
**Research Proposal Due Diligence Assessment**

<b>Part 1: General Information</b>	
<b>YODA Project (Protocol) ID:</b>	<b>2018-3011</b>
<b>Date:</b>	6 September 2018
<b>Product Name:</b>	Abiraterone acetate
<b>Therapeutic Area:</b>	Oncology
<b>Product Class:</b>	CYP17 inhibitor
<b>Condition(s) Studied:</b>	Prostatic Neoplasms
<b>Protocol Number(s) and Title(s):</b>	<p><b>NCT00638690/ COU-AA-301</b> - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy</p> <p><b>NCT00887198/COU-AA-302</b>- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</p>
<b>Part 2: Data Availability</b>	
<b>Question:</b>	<b>Response:</b>
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	
<b>Part 3: Data Availability Summary</b>	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
<b>Part 4: Proposal Review</b>	
<b>Question:</b>	<b>Response:</b>
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	Yes
Comments:	Janssen team performed a similar analysis on PSA and prepared a poster for ESMO 2018